Foundation Medicine Acquires Lexent Bio to Expand Multiomics Capabilities.

MANews-(C)2009-2020

Massachusetts, US-based molecular information company Foundation Medicine, Inc. has acquired California-based precision oncology company Lexent Bio, Inc., to accelerate liquid biopsy research and development, and advance cancer care, the company said.

Terms of the transaction were not disclosed.

This acquisition will accelerate Foundation Medicine's research and development strategy and expand the technology developed by Lexent Bio that complements Foundation Medicine's existing efforts and partnerships aimed at developing advanced diagnostics for physicians.

This technology adds to Foundation Medicine's portfolio of tissue and liquid biopsy platforms and will aim to support new approaches for developing targeted therapies, from discovery research through clinical development.

With this acquisition and the integration of...

To continue reading

Request your trial

VLEX uses login cookies to provide you with a better browsing experience. If you click on 'Accept' or continue browsing this site we consider that you accept our cookie policy. ACCEPT